Company ProfilePremium

Paragon Care Limited

Company Profile Analysis

Ticker: PGC.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Paragon Care Limited - Company showcase

Year Founded & Workforce

2008

1,292 Employees

Paragon Care Limited logo

Paragon Care Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Paragon Care Limited Overview

FieldDetailSource
Legal nameParagon Care LimitedFY26 Appendix 4E
Trading nameParagonCareFY25 Annual Report
ABN / ACNABN 76 064 551 426 / ACN 064 551 426FY26 Appendix 4E; 1H26 Investor Presentation
Former namesNot publicly disclosed in reviewed sources (no formal name change identified)—
Founding year (legacy Paragon Care)2008 (company "About" page)paragoncare.com.au
Founding year (CH2 / Clifford Hallam lineage)1918 ("We started out in Australia in 1918")FY25 Annual Report
Incorporation jurisdictionAustralia (Corporations Act 2001)FY25 Annual Report, Note 1
Registered office & principal place of business77–97 Ricketts Road, Mount Waverley, VIC 3149, AustraliaFY25 Annual Report, Note 1
Exchange / tickerAustralian Securities Exchange — PGC (secondary listing: Deutsche Börse ticker PXS, per Fintel)ASX; Fintel
ISINAU000000PGC4Fintel
CUSIPNot applicable / not publicly disclosed (Australian issuer)—
Fiscal year end30 JuneAnnual reports
Employees1,292 (FY25); "over 1,200" cited in FY25 Chair/CEO letter; FY24 and FY23 combined-group figures not publicly disclosedFY25 Annual Report
Gender split (FY25)51% male / 49% femaleFY25 Annual Report
AuditorErnst & Young (Melbourne; FY25 lead partner Paul Gower)FY25 Annual Report; FY26 Appendix 4E
Share registryNot re-verified for FY26 (FY22: Link Market Services)FY22 Annual Report
Shares on issue1,655,305,389 (weighted average FY25 and FY26; ~1.66bn)FY26 Appendix 4E, Part 17
Share price (latest verified)A$0.135 (4 Sep 2026); A$0.13–0.135 range Jul–Sep 2026.InvestSMART
Market capitalisation≈A$223m at A$0.135 (1,655.3m shares)InvestSMART; calculation
CEO & MDCarmen Riley (CEO from 1 Jul 2025; MD from 1 Mar 2026)ASX announcements 25 Jun 2025, 25 Feb 2026
ChairPeter LacazeFY25 Annual Report
Websitehttps://www.paragoncare.com.au—

The entity on the user's list (Paragon Care Limited, ASX: PGC, Australia) remains the same listed legal entity. Its trading name is now styled "ParagonCare". The website on the list (paragoncare.com.au) is current. No change of ticker or exchange has occurred. The economic business, however, is now dominated by the former Clifford Hallam Healthcare (CH2) pharmaceutical wholesale business following the June 2024 reverse acquisition.

ParagonCare is a mid-sized, founder-controlled Asia-Pacific healthcare distributor that combines a high-volume, thin-margin Australian pharmaceutical wholesale engine (inherited from Clifford Hallam Healthcare, Australia's only independent Community Service Obligation wholesaler) with a portfolio of higher-margin specialty businesses: medical technology agencies (imaging, devices, orthopaedics, robotics, vision, aesthetics, dental), third-party healthcare contract logistics, and TGA-certified clinical manufacturing of red-cell blood-bank reagents. FY26 revenue was A$3.68bn, but underlying EBITDA of A$97.2m represents a margin of only ~2.6%, and 96% of revenue still comes from Australia and New Zealand. Strategy is pivoting toward Asia, where six bolt-on acquisitions in FY26 lifted segment revenue 58% to A$160m at ~42% gross margin. The equity story is constrained by a A$38.0m credit loss on the collapsed Infinity Pharmacy Group, a statutory FY26 loss, leverage of ~2.5x, negative net tangible assets, no dividend, and a share price that has fallen roughly 60–70% from its post-merger implied level.


Company's own description

The FY25 Annual Report and FY26 Appendix 4E describe ParagonCare as one of Asia Pacific's leading diversified healthcare distributors and manufacturers, delivering pharmaceuticals, capital equipment, diagnostics, medical consumables, devices and complementary medicines, with origins in Australia in 1918 and a "transformational" 2024 merger of Clifford Hallam and ParagonCare. Its stated purpose is to make healthcare simpler, smarter and more accessible across Asia Pacific, and its vision is to be the region's most trusted and efficient diversified healthcare distribution and manufacturing partner (FY25 Annual Report).

The statutory principal-activities description (FY25 Directors' Report; FY26 Appendix 4E Part 8) is: supply of durable medical equipment, medical devices, consumable medical products and maintenance of technical medical equipment to the health, aged care (and aesthetics/veterinary) markets throughout Australia, New Zealand and Asia, plus distribution of pharmaceuticals, medical consumables and complementary medicines to the Australian healthcare market.

Go-to-market structure (four channels)

ChannelBusiness unitsCore customers
WholesalePharmacy; Medical Consumables; Complementary Medicines (Oborne, ParagonCare Prescribe); Dental Supplies (incl. AHP Dental)Independent retail pharmacies, non-affiliated and affiliated pharmacy groups (incl. second-line wholesaling), public and private hospitals, aged care, primary care, allied health, naturopaths/TCM practitioners, dental clinics
Medical TechnologyOEM Capital (imaging, PACS); OEM Devices (infusion, oncology, neonatal, surgical, critical care, urology); Vision; Aesthetics; Surgical Implants/Orthopaedics; Surgical Robotics (CMR Surgical); ServicePublic/private hospitals, day surgeries, orthopaedic surgeons, optometrists/ophthalmologists, dermatologists/cosmetic clinics, imaging departments
Contract Logistics3PL/4PL services for healthcare suppliers (e.g., Owens & Minor from June 2025; Pacific Medical in Hong Kong from Feb 2026)Pharmaceutical and medtech manufacturers, public health distribution centres, pharmaceutical wholesalers
Clinical ManufacturingImmulab red-cell reagent manufacturing; contract manufacturing (first agreement FY25); diagnostic instruments & consumables distribution; Fisher Biotec (acquired Jan 2026)Pathology labs, blood banks, IVF clinics, microbiology labs, universities, hospitals

Following a FY25 restructuring, the group operates through four go-to-market channels supported by shared services (Finance, IT, Marketing, Customer Service, Supply Chain, Commercial, Procurement):

(Source: FY25 Annual Report, "Business Focus" and "Customer Networks" pages; FY26 Results Release.)

Revenue model and value-chain position

Revenue type (AUD Mn)FY25FY26
Goods (point in time)3,580.13,652.3
Services (over time)33.828.3
Total revenue3,613.93,680.5
Supplier rebates (memo)417.2450.9

The revenue model is overwhelmingly product resale (point-in-time recognition). In FY26, goods transferred at a point in time were A$3,652.3m (99.2%) and services transferred over time were A$28.3m (0.8%), versus A$3,580.1m and A$33.8m in FY25 (FY26 Appendix 4E, Part 9). There is no material subscription or licensing revenue. Supplier rebates are a critical economic lever: rebates of A$450.9m in FY26 (A$417.2m in FY25) offset a gross cost of inventories sold of A$3,787.8m, meaning rebates are larger than the group's entire gross margin (A$347.5m) (FY26 Appendix 4E, Part 9b).

ParagonCare sits in the mid-stream distribution layer of the healthcare value chain: it buys from originator and generic pharmaceutical manufacturers, global medtech OEMs (for which it often holds exclusive regional agency rights) and private-label sources, and sells to pharmacies, hospitals and clinics. Upstream, it manufactures a narrow line of in-vitro diagnostic reagents (Immulab) and offers contract manufacturing. Sideways, it monetises its warehouse network by providing contract logistics to other suppliers.

Independent characterisation

Economically, ParagonCare is two businesses wearing one ticker:

  1. A scale-dependent ANZ pharmaceutical and consumables wholesaler (Wholesale channel ≈A$3.0bn of FY25 revenue, ≈82% of group) operating at a channel margin of ~6.0–6.3% (FY26 Results Release) and ANZ segment margin of ~8.0%, competing against far larger incumbents (EBOS/Symbion, Sigma/Chemist Warehouse, Wesfarmers Health/API). This business generates revenue mass, supplier rebates and CSO funding but very little operating profit after warehouse, freight and finance costs.

  2. A specialty distribution and manufacturing portfolio (MedTech ~39–41% channel margin, Clinical Manufacturing ~44–46%, Asia ~42–46%) that likely produces the majority of group gross profit dollars outside wholesale, and which is the explicit focus of capital allocation.

The credit event with Infinity Pharmacy Group (a Priceline franchisee) illustrates the principal structural risk of the wholesale model: very large receivable exposures to individual pharmacy groups relative to the group's thin equity cushion.

End-markets served

Retail community pharmacy (independent and banner groups), hospital pharmacy (public and private), acute hospitals (capital, devices, implants), aged care and community care, primary care and allied health, dental, aesthetics/dermatology, optometry/ophthalmology, pathology/blood banking, IVF, defence (5-year Australian Defence Force supply contract from Q4 FY26), and B2B logistics for healthcare manufacturers. Geographic end-markets: Australia, New Zealand, Thailand, South Korea, Japan, Philippines, Vietnam, and (via FY26 acquisitions) Singapore, Malaysia, Indonesia, Hong Kong/Macau. The 1H26 presentation cites a presence in nine Asian countries.

Strategy

Stated strategy themes

"3-2-1" (three businesses, two years, one team): the integration programme for ParagonCare, CH2 and Oborne, declared complete in FY26 with synergies "in line with strategy". The 1H26 release targeted A$12m of synergy benefits by FY26 (after A$5m targeted in FY25).

Strategic positioning statements (FY25 AR): be the leading independent wholesaler and distributor in APAC; be the master franchise holder for APAC agency arrangements; be the best-in-class red-cell diagnostics manufacturer in APAC; offer specialist contract logistics with an integrated service model.

Values: Accountable, Discipline, Empowerment, Initiating, Communication.

FY27 priorities (FY26 Results Release outlook)

PillarInitiatives
Geographic & market expansionGrow Asia regional presence; leverage acquired businesses; enter new markets; expand aesthetics, dental and animal health; launch NZ wholesale channel; strategic M&A
Growth initiativesProduct expansion and capability-led organic growth; profitable-revenue focus; enhanced go-to-market; new website and digital marketing; new supplier agreements
Operational excellenceSydney warehouse strategic review (new site FY28); offshoring ANZ administration to Asian shared-service offices; technology investment
Capital managementEmployee Share Trust to offset EIP dilution; share buyback to commence in FY27; dividend review at 1H27 results

Initiatives in the last 24 months

DateInitiativeType
FY25Restructure into four channels with shared servicesTransformation
FY25JDE ERP migration of Oborne, DFV, REM, WBM, SMS, Surgical SpecialtiesPlatform
May 2025Dental BU launch (ANZ)New business
FY25Aesthetics BU launch in ANZ (Classys, Neauvia)New business
FY25–FY26Surgical robotics entry with CMR SurgicalNew business / partnership
FY25First contract-manufacturing agreement at Mount WaverleyNew business
Jun 2025Owens & Minor 4PL contractContract win
Jun 2025Refinancing: A$325m DFF + A$75m ABFCapital
FY25Seven sites consolidatedCost
FY25–FY26Brisbane automated DCPlatform
FY26Regional Asian management team and multi-disciplinary shared servicesTransformation
Jan 2026Exit of low-margin Ramsay contractPortfolio pruning
FY26Six Asian/ANZ acquisitions (see Section 11)M&A
Q4 FY26Australian Defence Force 5-year contractContract win
FY27Buyback, Employee Share TrustCapital management

ESG commitments

Net zero by 2050 ambition; solar programme for warehouses in development; CSR policy (2022); Modern Slavery statement and supplier questionnaire (FY25 AR).

Medium-term targets and guidance

ItemDetail
FY26 guidance (given Feb 2026)Revenue A$3.6–3.7bn; underlying EBITDA A$97–107m — revenue achieved (A$3.68bn); EBITDA at bottom of range (A$97.2m)
FY27 guidanceNot provided "due to economic instability"; expectation of mid-single-digit revenue growth
LeverageFY26 year-end target of 2.5x net debt / underlying EBITDA (incl. LTM of acquisitions) met
Medium-term financial targets—

Products & Services

Pricing models are not publicly disclosed for any product line; the company acts largely as a reseller or exclusive agent at negotiated contract prices (hospital tenders, pharmacy trading terms, PBS-regulated pricing for prescription medicines).

Wholesale channel

OfferingDescription & capabilitiesTarget customerNotes / flagship
Pharmacy wholesale (CH2)Full-line pharmaceutical wholesaling including PBS medicines; member of Commonwealth CSO and NDSS funding poolsIndependent pharmacies, banner groups, hospital pharmaciesDescribed as Australia's only independent CSO wholesaler (FY25 AR); total pharmacy sales ≈A$2.8bn in FY25 (+11.6%)
Vantage programLow-cost wholesale plus centralised technology platform for independent pharmaciesIndependent pharmaciesGrew to service more than 500 pharmacies in FY25
Hospital pharmacy supplyFirst-line and second-line wholesale to hospitalsPublic and private hospitalsMarket-share gains in FY25 incl. a first-line partnership; Ramsay contract exited Feb 2026
Medical Consumables (incl. Specialist Medical Supplies)Broad consumables range including private-label linesAged care, community and primary care, allied health, dentalIntegrated onto JDE ERP in FY25; ordering via CH2 Direct e-commerce
CH2 DirectB2B e-commerce ordering platformAll wholesale customersDigital procurement access
Complementary Medicines (Oborne Health Supplies)Distribution of vitamins, herbal/natural medicines, nutritionPractitioners, naturopaths, TCM, pharmacies, retailAdelaide and Newcastle footprint added FY25
ParagonCare PrescribePractitioner prescribing and direct-to-patient delivery of therapeutic goodsIntegrative practitioners and patientsRelaunched FY25
Dental Supplies (incl. AHP Dental & Medical, Presidental)Dental consumables and equipment; AHP carries 7,000+ products from 50+ brands to 2,500+ customersPrivate dental clinics, corporate dental groups, teaching institutionsBU launched May 2025; AHP acquired Jul 2025
NZ wholesalePharmac-listed consumables; strategic supplier to largest NZ private hospital groupNZ public and private hospitalsNZ wholesale channel launch flagged for FY27
Defence supply5-year Australian Defence Force supply contractAustralian Defence ForceCommenced Q4 FY26; annual value ~A$40m per one aggregator

Medical Technology channel

OfferingDescription & capabilitiesTarget customerNotes / flagship brands (as disclosed)
OEM Capital – imagingUltrasound, radiology, surgical and molecular imaging, AI solutions, PACSHospital imaging departments, private practiceSamsung ultrasound (NZ clinical support); Carestream; new imaging agreements in Philippines and Japan; retrofit digital solutions in Japan
OEM Devices – infusionAmbulatory and home infusionHospital-in-the-home, regional anaesthesia, home parenteral nutritionAvoset Infusion System launched FY25; >250 Sapphire MT pumps deployed nationally for HPN
OEM Devices – oncologyClosed-system drug transfer devices (CSTD)Hospital oncology/pharmacyClaimed national CSTD leadership; NSW share gains
OEM Devices – neonatalNICU camera monitoring, phototherapy, newborn hearing screeningNeonatal unitsAngelEye NICU video camera introduced FY25
OEM Devices – vascular access, critical care, surgical, urologyConsumable and device portfoliosAcute hospitalsVietnam catheter fixation expansion FY26
Surgical roboticsRobotic-assisted soft-tissue surgeryANZ hospitalsCMR Surgical partnership; entry FY26
Orthopaedics / surgical implantsJoint replacement implants, navigation/robotics, orthobiologicsOrthopaedic surgeons, hospitals, day surgeriesCorin second-generation knee robotics launched in NZ; renewed exclusive agreements in Australia; orthobiologics relocated to Eastern Creek
Vision (Designs for Vision)Ophthalmic diagnostics and surgical equipmentOptometrists, ophthalmologists, day surgeries, universitiesSurgical and diagnostic vision combined under one leadership in FY25; FY26 headwinds from OEMs going direct
AestheticsEnergy-based devices (HIFU, monopolar RF, microneedle RF), injectables/fillers, skin boosters, cosmeceuticalsClinics, dermatologists, cosmetic surgeonsClassys devices and Neauvia injectables in ANZ; >40% HIFU share in Vietnam (company claim); Haju Medical (Indonesia/Korea buying house) acquired Apr 2026
Service & TechnologyEquipment management, repair and maintenance, OEM service representation, telecommunications, access control, nurse-call/patient monitoringHospitals and healthcare facilitiesImage Space (NZ capital service) acquired FY25; service revenue declining structurally (HY25/FY25 releases)
Asia medtech distribution (Quantum, Somnotec, Pacific Medical, Transpacific)Imaging, interventional cardiology, oncology, sleep/respiratory and other device distributionHospitals in SE/North AsiaKorea: innovative surgical table, endoscopy consumables; Thailand: Good Distribution Practice preparation

Clinical Manufacturing channel

OfferingDescription & capabilitiesTarget customerNotes
Immulab reagent red cellsManufacture of in-vitro diagnostic red-cell reagents for blood-group serologyBlood banks, pathology labs, hospitalsSupports Australia's self-sufficiency in blood screening reagents; key supply agreement renewed FY25
Contract manufacturingThird-party manufacturing at TGA-certified Mount Waverley facilityIVD/medical manufacturersFirst agreement signed FY25
Diagnostics distributionDiagnostic instruments and consumablesPathology, IVF, microbiology, universitiesNew specialised-diagnostics partnerships FY25
Fisher BiotecMolecular biology/laboratory products (acquired 30 Jan 2026)LaboratoriesDrove double-digit channel growth in FY26

Contract Logistics channel

OfferingDescription & capabilitiesTarget customerNotes
3PL/4PL healthcare logisticsWarehousing, temperature-controlled storage, S8 secure storage, distributionGlobal pharma/medtech suppliers, public health DCs, wholesalersOwens & Minor 4PL from June 2025; >98% on-time delivery for key pharmaceuticals (company claim); team doubled in FY25
Hong Kong/Macau logistics (Pacific Medical / MD Medical Logistics)Contract logistics plus OEM agencies in interventional cardiology and oncologyHK/Macau hospitals and suppliersAcquired Feb 2026

Legacy Paragon brand inventory

Brands historically operated by legacy Paragon Care (IBISWorld/company listings): Designs for Vision, Electro Medical Group, Immulab, Immuno, Insight Surgical, LabGear, Lovell Surgical Solutions, Meditron, MedTech Solutions, Medtek, Quantum Healthcare, REM Systems (medical and veterinary), Scanmedics, Specialist Medical Supplies, Surgical Specialties, Total Communications, Western Biomedical. Several have been integrated into the JDE ERP and channel structure (Oborne, Designs for Vision, REM Australia, WBM, SMS and parts of Surgical Specialties in FY25).

Financial Narrative

Basis: FY24–FY26 are statutory (FY26 Appendix 4E; FY25 Annual Report). FY22–FY23 are CH2-predecessor figures from stockanalysis.com (aggregator; not reconciled to a primary filing) and are flagged. Blank cells = not publicly disclosed or not verifiable. All figures A$m unless stated.

Income statement

FY24 underlying EBITDA of A$53.0m is the statutory-basis normalisation; the company's FY24 pro-forma (full year of all three businesses) figures were revenue A$3,336.3m and underlying EBITDA A$92.4m (FY25 Results Release). FY24 dividends of A$12.6m were paid by CH2 to its pre-merger owners, not to PGC shareholders.

Margins and growth

Revenue CAGR FY22–FY26: ≈21.2% (A$1,708m → A$3,680.5m), overwhelmingly acquisition- and merger-driven. On the company's pro-forma basis, FY24→FY26 growth is ≈5.0% p.a. (A$3,336m → A$3,681m), and normalised organic growth in FY26 was 6.7%.

Underlying-to-statutory EBITDA bridge

(FY26 Appendix 4E Part 2; FY25 Annual Report Directors' Report.) Gross ECL expense recognised in FY26 was A$38.0m (A$47.3m in 1H26 less a A$9.3m reversal in 2H26), shown net of A$3.1m recoverable GST as A$34.9m in the bridge.

Balance sheet

FY23 equity of A$18.9m is CH2's opening equity at 1 July 2023 (FY25 AR statement of changes in equity). The negative statutory working capital reflects classification of the debtor finance facility as current (going-concern note); company-defined NWC includes A$22.2m deferred consideration and is shown net of the A$39.2m Infinity ECL.

Ratios (calculated by analyst from statutory data)

FY24 ratios are distorted by the reverse-acquisition basis (12 months of CH2 revenue against a year-end balance sheet that includes all of legacy Paragon). Underlying ROIC for FY25 uses underlying EBITDA 95.2 less D&A 29.8.

Commentary on trends, inflections and drivers

Revenue. The step-changes in FY23–FY25 reflect CH2's own growth and acquisitions (Oborne) followed by the merger. FY26 is the first "clean" comparison and shows only 1.8% headline growth because roughly A$230m of annualised Ramsay revenue and the residual Infinity revenue fell away; normalised organic growth of 6.7% and like-for-like-currency underlying EBITDA growth of 7.4% indicate the core is growing, but from a low-margin base.

Gross margin inflection. Gross margin rose from ~6% to 9.4% because the merger added higher-margin specialty businesses and because low-margin wholesale contracts (Ramsay) were exited. This mix shift is the most important positive trend in the numbers.

Operating leverage is negative. Despite gross profit growing A$23.5m in FY26, warehousing and distribution costs rose A$8.8m (fuel and outside-storage costs ahead of the delayed Brisbane DC), employee costs rose A$10.8m, and administration costs more than doubled (driven by the A$38.3m ECL line, but other corporate costs also rose from A$7.3m to A$14.8m and advertising from A$10.7m to A$12.7m). D&A rose 24.9% as acquired supplier-contract intangibles were amortised faster and right-of-use assets grew with the new DC.

Finance costs are the binding constraint. Finance costs of A$35.2m consume more than one-third of underlying EBITDA; interest on bank borrowings alone was A$23.0m, plus A$7.7m of merchant and other finance charges. With the facilities priced at BBSY + 3.05%, every 100bp of base-rate movement on ~A$290m of drawn bank debt is worth roughly A$2.9m pre-tax.

Balance sheet quality is weakening. Equity fell A$34.0m in FY26 (loss plus A$19.4m FX translation loss), goodwill and intangibles rose A$54.2m on acquisitions, and NTA per share deteriorated to −8.59 cents. Vendor contingent consideration rose from A$4.1m to A$56.0m, a deferred cash claim not included in reported net debt. Market capitalisation fell below book value at 30 June 2026, which the company treated as an impairment indicator, but its value-in-use test (FY27–FY31 plan) showed headroom.

Cash flow is recovering but thin. OCF improved to A$29.1m (+317% vs the A$7m pro-forma-type comparison cited by the company; statutory swing from −A$13.4m), but after A$33.2m of capex (mainly the Brisbane DC) free cash flow was still negative, and A$51.4m of acquisitions were debt-funded.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Margin Analysis (%)

MetricFY22FY23FY24FY25FY26

Revenue (AUD Mn)

1,7082,1872,969.93,613.93,680.5

Revenue growth (%)

5.628.035.821.71.8

Gross profit (AUD Mn)

110.9131.4176.5324.0347.5

Operating income / EBIT (AUD Mn; FY24–26 = PBT + finance costs)

18.129.129.858.613.5

Statutory EBITDA (AUD Mn; FY22–23 aggregator definition)

21.933.544.588.550.8

Underlying EBITDA (AUD Mn; company)

——53.095.297.2

Pre-tax income (AUD Mn)

10.918.413.825.5-21.7

Net income (AUD Mn)

7.612.88.220.6-16.0

Underlying NPAT (AUD Mn; company)

———31.226.0

EPS basic (A cents)

——0.871.24-0.97

EPS diluted (A cents)

——0.871.24-0.97

Dividends per share (A cents)

——000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY22FY23FY24FY25FY26

Gross margin (%)

6.506.015.948.979.44

Operating (EBIT) margin (%)

1.061.331.001.620.37

Statutory EBITDA margin (%)

1.281.531.502.451.38

Underlying EBITDA margin (%)

———2.632.64

Net margin (%)

0.440.580.280.57-0.44

Financial Analysis

ItemFY25FY26

Statutory EBITDA

88.550.8

Infinity provision (net of GST)

0.034.9

M&A and related costs

0.04.7

Restructuring and integration

2.86.4

FX hedges / currency remeasurement

3.9-1.6

Share-based payments

0.01.9

Underlying EBITDA

95.297.2

Balance Sheet and Per-Share Data

MetricFY23FY24FY25FY26

Total assets (AUD Mn)

—1,150.61,243.71,373.4

Cash & equivalents (AUD Mn)

—19.920.323.7

Borrowings – current (AUD Mn)

—106.7160.4222.6

Borrowings – non-current (AUD Mn)

—89.976.485.2

Total borrowings (AUD Mn)

—196.6236.7307.7

Net debt ex-leases (AUD Mn)

—176.6216.4284.1

Lease liabilities (AUD Mn)

—54.555.681.2

Vendor conditional payables (AUD Mn)

—4.24.156.0

Total equity (AUD Mn)

18.9291.7329.8295.9

Goodwill & intangibles (AUD Mn)

—389.2395.5449.7

Inventories (AUD Mn)

—270.4282.5342.1

Trade & other receivables – current (AUD Mn)

—346.0401.5370.7

Trade & other payables (AUD Mn)

—553.5575.8601.2

Statutory working capital (current assets less current liabilities, AUD Mn)

—-24.7-14.0-104.8

Company-defined net working capital (AUD Mn)

——126.094.1

NTA per share (A cents)

——-3.30-8.59

Cash Flow

MetricFY24FY25FY26

Operating cash flow (AUD Mn)

44.5-13.429.1

Capex – PP&E (AUD Mn)

6.811.730.6

Capex – intangibles (AUD Mn)

12.55.22.6

Free cash flow (OCF less capex, AUD Mn)

25.1-30.3-4.1

Lease principal repaid (AUD Mn)

8.011.013.3

Acquisitions, net of cash (AUD Mn)

25.10.551.4

Dividends paid (AUD Mn)

12.600

Share buybacks (AUD Mn)

000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY24FY25FY26

ROE (% ; NPAT / average equity)

5.36.6-5.1

ROA (% ; NPAT / average assets; FY24 end-period)

0.71.7-1.2

ROIC (% ; statutory EBIT x 0.7 / (equity + net debt))

4.57.51.6

ROIC underlying (% ; (underlying EBITDA − D&A) x 0.7 / IC)

—8.67.2

Current ratio (x)

0.960.980.88

Debt / equity (x ; borrowings only)

0.670.721.04

Net debt / statutory EBITDA (x)

3.972.455.59

Net debt / underlying EBITDA (x ; analyst)

—2.272.92

Net debt / underlying EBITDA (x ; company, incl. LTM of acquisitions)

1.912.262.50

Interest coverage (x ; statutory EBIT / finance costs)

1.861.770.38

Interest coverage underlying (x)

—1.971.70

Asset turnover (x)

2.583.022.81

DSO (days ; trade receivables / revenue)

—34.636.5

DIO (days ; inventory / COGS)

—31.337.5

DPO (days ; trade & other payables / COGS)

—63.965.8

Cash conversion cycle (days)

—2.08.2

Region revenue (AUD Mn)

Region revenue (AUD Mn)FY25FY26

Australia

3,452.63,460.8

New Zealand

60.059.6

Asia

101.3160.1

Total

3,613.93,680.5

Growth / mix (%)

Growth / mix (%)FY25FY26

Australia growth (%)

—0.2

New Zealand growth (%)

—-0.6

Asia growth (%)

20.658.0

Australia share (%)

95.594.0

New Zealand share (%)

1.71.6

Asia share (%)

2.84.3

Region non-current assets (AUD Mn)

Region non-current assets (AUD Mn)FY25FY26

Australia

415.9362.4

New Zealand

32.627.8

Asia

35.6200.2

Share Price History

DatePriceContextSource

Jun 2024

≈0.36 implied

A$600m post-merger market cap ÷ ~1.66bn shares

Baker McKenzie; calc.

Dec 2025 (pre-receivership)

≈0.25–0.26

Shares had lost >50% since start of 2025

Business News Australia

17 Dec 2025

0.22–0.235 intraday

Infinity receivership

Press

2 Jan 2026

0.215

2026 opening price

InvestSMART

2026 high

0.255—

InvestSMART

24 Feb 2026

0.21

Pre-1H26 results

Motley Fool

26 Feb 2026

0.19

Post-1H26 results

Motley Fool

12 Mar 2026

0.17

1-year return −55.1%; 52-week high 0.45

Simply Wall St

7 Aug 2026

0.13

2026 low 0.125

InvestSMART

4 Sep 2026

0.135

Latest verified; market cap ≈A$223m

InvestSMART

Performance metric

Value

——

2026 YTD to Aug 2026 (%)

-39.5——

1-year to Mar 2026 (%)

-55.1——

Since merger completion (Jun 2024 implied ~0.36 to 0.135, %)

-62.5——

Valuation Snapshot

MultipleValueBasis

Market capitalisation (AUD Mn)

223

1,655.3m shares

Enterprise value ex-leases (AUD Mn)

507
  • net debt 284.1

EV incl. leases and earn-outs (AUD Mn)

644
  • leases 81.2 + vendor payables 56.0

EV / underlying EBITDA (x)

6.6

644 / 97.2 (post-AASB 16 consistent)

EV / underlying EBITDA ex-leases (x)

5.2

507 / 97.2

EV / Sales (x)

0.14

507 / 3680.5

P/E underlying (x)

8.6

223 / 26.0

P/B (x)

0.75

223 / 295.9

Dividends & Capital Returns

ItemFY24FY25FY26

Dividend per PGC share (A cents)

000

Dividends paid (AUD Mn; FY24 = CH2 pre-merger owners)

12.600

Buybacks (AUD Mn)

000

Debt Facilities

FacilityLimitDrawnMaturityPricingCovenants

Debtor Finance Facility (ScotPac)

A$325.0m (min. draw A$125m; limited by eligible receivables)

A$206.2m

12 Jun 2028 (voluntary prepayment from 12 Jun 2027)

BBSY + 3.05%

Nil

Asset Based Facility

A$75.0m

A$75.0m (fully drawn)

12 Jun 2028

BBSY + 3.05%

Nil

Thailand trade finance

US$17m committed + US$10m uncommitted

US$10.0m (A$14.4m)

180-day terms

Commercial

None; PGC guarantee up to US$10m

NZ revolving credit

NZ$12.0m

A$9.8m (fully drawn)

Amortising from 13 months after draw

Commercial

Interest cover and leverage (complied)

Hire purchase

A$3.0m

A$1.5m

Various

——

American Express purchasing

A$8.0m

Nil

35 days post statement

1.45% fee

—

Debt maturity (AUD Mn)

FY27

FY28

———

Current borrowings (contractual/classification)

222.6————

Non-current borrowings

—85.2———

Analyst Conclusions

Management guidance

No quantitative FY27 guidance (withheld due to "economic instability"); management expects mid-single-digit revenue growth, continued underlying organic revenue and earnings growth, ongoing supply-chain disruption, continued M&A, buyback commencement and a dividend review at 1H27. FY26 guidance was met on revenue and at the bottom of the range on underlying EBITDA.

Consensus

Consensus forecasts are not publicly disclosed in reviewed sources (the most recent aggregator view, Aug 2025, implied ~5% revenue growth).

Bull case

  1. Earnings base is cleaner than the statutory loss suggests. Strip out the A$34.9m net Infinity charge and FY26 underlying EBITDA of A$97.2m grew 7.4% in constant currency; with Ramsay gone, Brisbane DC live and a full year of Haju (A$28.8m annualised revenue uplift at high margin), FY27 underlying EBITDA could plausibly exceed A$105m.

  2. Mix shift toward Asia and specialty raises quality. Asia already earns more statutory EBITDA (A$32.0m) than ANZ; each A$100m of Asian revenue at ~42% gross margin is worth far more than wholesale revenue at ~6%.

  3. Valuation is undemanding. At ~0.75x book, ~8.6x underlying earnings and ~5–6.6x EV/EBITDA, small improvements in cash conversion, a successful buyback and any Infinity recovery above A$9.3m could re-rate the stock.

Bear case

  1. Leverage plus thin margins equal fragility. Net debt of A$284m plus A$81m of leases and A$56m of earn-outs against A$97m of underlying EBITDA; statutory interest cover of 0.38x in FY26; another credit event comparable to Infinity would erase a year's earnings.

  2. Wholesale is structurally disadvantaged. The group lost Ramsay on price, has an independent-pharmacy customer base under consolidation pressure, and competes against peers with 3–4x the scale and far stronger balance sheets.

  3. Governance and disclosure quality discount is warranted. One independent director, a qualified FY25 audit, two CFO exits, discretionary bonuses despite missed gateways, negative NTA and a debt-funded acquisition spree with large provisional goodwill all justify a persistent discount.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableTiming
Infinity store-sale completions and final recovery vs A$9.3m bookedSep–Dec 2026
FY26 Annual Report: audit opinion (clean vs qualified), FY26 KMP remunerationReleased 29 Sep 2026
2026 AGM: remuneration vote (first-strike risk), trading updateExpected Nov 2026
CFO appointmentOpen
Buyback launch and sizeFY27
1H27 results: dividend decision, net working capital, leverage trajectoryFeb 2027
ADF contract ramp-up; NZ wholesale launch; PMC ANZ commencement1H FY27
Somnotec Thailand completionFY27
Earn-out payments (A$22.3m current)FY27
Facility optionality (prepayment window opens 12 Jun 2027) and refinancing ahead of Jun 2028 maturity2,027
Sydney warehouse decisionFY27 for FY28 go-live

Analyst verdict

ParagonCare is a strategically coherent but financially stretched mid-cap distributor whose equity has been re-priced to reflect execution and credit risk rather than its underlying earnings power. The 2024 reverse merger achieved its operational objectives: the three businesses are on one ERP, synergies were delivered, low-margin contracts have been pruned and gross margin has risen from roughly 6% to 9.4%. Underlying EBITDA has been stable at A$95–97m for two years, and the Asian platform is now genuinely material, producing more statutory EBITDA in FY26 than the far larger ANZ business.

The problem is the conversion of that EBITDA into shareholder value. Finance costs absorb more than a third of underlying EBITDA, depreciation is rising with new warehouses and acquired intangibles, contingent consideration has ballooned, tangible equity is negative, and the Infinity collapse exposed weak credit controls and a board without the independent oversight one would expect of a A$3.7bn-revenue business. Revenue growth in ANZ is near zero once lost contracts are included, and management has declined to give earnings guidance.

At roughly A$0.135, the market values the company at about 0.75x book and about 6.6x fully-loaded EV/EBITDA, which already discounts a great deal. The near-term path to a re-rating requires three things: a clean FY26 audit opinion and an Infinity recovery at or above the booked A$9.3m; demonstrable free cash flow in FY27 (positive after capex, leases and earn-outs) that allows leverage to fall below 2.5x without asset sales; and governance reform, most obviously the appointment of additional independent directors and a permanent CFO. Absent those, the founder-controlled register and limited float make the stock a value trap rather than a value opportunity.

Overall stance: speculative, catalyst-dependent. Constructive only for investors who can underwrite balance-sheet risk and governance concentration; cautious for everyone else until FY27 cash generation is evidenced.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground / educationIndependenceShareholding

Peter Lacaze

Non-Executive Chair; Chair, Nomination & Remuneration Committee; member, Audit & Risk Committee

PGC board since Jun 2024; CH2 Chair since Dec 2015

BCom, MBA, MAICD, FCPA; CH2 CEO 2006–08; career across healthcare and travel

Not independent (≈28.5% holder)

471,762,036 shares (FY25 AR)

David Collins

Executive Director (was CEO & MD to 30 Jun 2025; MD to 28 Feb 2026)

PGC board since Jun 2024; CH2 since 2005

BBus; CH2 CFO from 2005, MD 2008–14 and from 2015; former CFO Greencross Health (Auckland)

Not independent (executive; ≈28.5% holder)

471,762,036 shares

Carmen Riley

CEO (from 1 Jul 2025) and Managing Director (from 1 Mar 2026)

CH2 board from Jul 2019; ~15+ years at CH2

BCom, CPA, GAICD; former CEO of PQ Lifestyles (Intouch); FMCG supply-chain, finance and project management background

Not independent (executive)

438,888 shares and 4,462,144 performance rights (FY25 AR); 5,996,911 shares issued 3 Jul 2026

John Walstab

Non-Executive Director (from 1 Apr 2025)

PGC board since Feb 2022

Founder and former MD/CEO of Quantum Health Group; PGC MD 2023–Jun 2024; ex-MD ATL (Philips Medical Systems ANZ)

Not independent (former executive within 3 years; ≈8.7% holder)

144,591,185 shares (FY25 AR)

Peter Egglestone

Independent Non-Executive Director; Chair, Audit & Risk Committee

Since 20 Mar 2025

25+ years finance/commercial leadership; former CEO of a payments facilitator; former C-suite at Journey Beyond

Independent

100,000 (FY25); bought 200,000 in Jun 2026

Former: Alan McCarthy

NED

Feb 2022 – 31 Mar 2025

Former MD Philips ANZ, VP Asia Pacific CareFusion

Was independent

—

Executive Leadership Team

NameTitleTenure / notesSource

Carmen Riley

CEO & Managing Director

CEO 1 Jul 2025; MD 1 Mar 2026; 12-month notice

ASX 25 Feb 2026

David Collins

Executive Director

Transitioned from MD 1 Mar 2026

ASX 25 Feb 2026

Chief Financial Officer

—

ASX 15 Oct 2025

—

Michael Sapountzis

Company Secretary (Vistra)

Since 22 Nov 2024

FY25 AR

Investor relations

Howard Marks, Automic Group

—

FY26 Appendix 4E

Directors' Remuneration

NameSalary & feesBonusNon-monetaryTerminationSuperLSLShare-basedTotal

Peter Lacaze (Chair)

134,52900015,47100150,000

David Collins (CEO/MD)

780,364408,25082,501030,00012,86101,313,976

Carmen Riley (COO/ED)

559,54600030,00016,6301,108,1191,714,295

John Walstab (exec to 31 Mar 2025)

397,840220,26750,000220,01729,9326,5630924,619

John Walstab (NED from 1 Apr 2025)

16,8160001,9340018,750

Peter Egglestone (NED)

18,8860002,1720021,058

Alan McCarthy (NED)

56,25000000056,250

Marcus Crowe (CFO, from 1 Mar 2025)

159,12700011,5092,3340172,969

Michael Peters (CFO, to 6 Sep 2024)

86,7890007,4830094,272

Total KMP

2,210,147628,517132,501220,017128,50138,3881,108,1194,466,189

Major Shareholders

HolderShares% of 1,655.3mSource

Peter Lacaze (and related)

471,762,03628.5

FY25 AR

David Collins (and related)

471,762,03628.5

FY25 AR

John Walstab (and related)

144,591,1858.7

FY25 AR

Carmen Riley

≈6.4m (438,888 + 5,996,911 issued Jul 2026)

0.4

FY25 AR; Motley Fool director dealings

Peter Egglestone

≈300,000

0.02

FY25 AR; Jun 2026 trade

Competitive Landscape

Competitor Detail

ChannelCompetitorType / positioningComparative scale (where verified)

ANZ pharmaceutical wholesale

EBOS Group (Symbion, NZX/ASX: EBO)

Largest ANZ healthcare distributor; CSO wholesaler

FY26 revenue A$13,487m; underlying EBITDA A$614m (4.6%); Healthcare segment A$12,580m

ANZ pharmaceutical wholesale/retail

Sigma Healthcare (ASX: SIG, incl. Chemist Warehouse)

Vertically integrated wholesaler-franchisor

FY26 revenue A$10.8bn; normalised EBIT A$1,090m (10.1%)

ANZ pharmaceutical wholesale

Wesfarmers Health (API / Priceline)

CSO wholesaler and banner owner; Infinity's primary wholesaler

—

ANZ medical consumables

Medline, Cardinal Health, Bunzl Healthcare, Independence Australia, Team Medical Supplies

Global/regional consumables distributors

—

ANZ medtech agencies

Device Technologies, LifeHealthcare (private), and OEMs going direct (Medtronic, Stryker, J&J MedTech, Zeiss, etc.)

Specialty distributors and manufacturers

—

Asia medtech/healthcare distribution

DKSH (SIX: DKSH), Zuellig Pharma

Pan-Asian market-expansion service providers

—

Contract logistics

DHL Supply Chain, EBOS, Sigma, Movianto-type 3PLs

Healthcare 3PL/4PL

—

Blood-bank reagents

Bio-Rad, Grifols, Ortho Clinical Diagnostics (QuidelOrtho), Immucor/Werfen

Global IVD manufacturers

—

Complementary medicines distribution

Pharmacy wholesalers and direct brand distribution

——

Peer Comparison FY2026

MetricParagonCareEBOS GroupSigma Healthcare

Revenue

3,680.513,48710,800

Revenue growth (%)

1.89.915.5

Underlying EBITDA

97.2614—

Underlying EBITDA margin (%)

2.64.6—

Normalised EBIT

59.9465.81,090

Normalised EBIT margin (%)

1.63.510.1

Net debt / EBITDA (x, company basis)

2.52.10.57

Company Snapshot

$2,374.5M

Revenue

1,292

Employees

2008

Founded

Mount Waverley, Australia

Headquarters

SWOT Analysis

Strengths

  • Scale entry ticket: FY26 revenue A$3.68bn and A$451m of supplier rebates provide purchasing relevance (FY26 4E).
  • Margin mix improving: gross margin rose from 5.9% (FY24) to 9.4% (FY26) as specialty businesses were added and low-margin contracts exited.
  • Unique CSO position: described as Australia's only independent CSO wholesaler; Vantage serves >500 independent pharmacies (FY25 AR).
  • High-margin Asian platform: Asia gross margin 42.1%, segment EBITDA A$32.0m on A$160.1m revenue (20% EBITDA margin) — exceeding ANZ statutory EBITDA in FY26.
  • Contract logistics momentum: +25% in FY25 to A$336m and +47.1% in 1H26 to A$235.5m (company releases), with margin rising to 4.3%.
  • Niche manufacturing moat: TGA-certified Mount Waverley plant; Clinical Manufacturing margin 46.4% (FY26).
  • Owner alignment: board and management own ≈66% of shares, limiting agency costs between owners and managers.

Weaknesses

  • Thin profitability: underlying EBITDA margin 2.6%; statutory EBIT margin 0.37% in FY26.
  • Finance-cost burden: A$35.2m finance costs vs A$59.9m underlying EBIT (1.7x cover).
  • Negative tangible equity: NTA −8.59 cents per share; goodwill and intangibles A$449.7m exceed equity A$295.9m.
  • Governance: one independent director of five; FY25 qualified audit opinion; discretionary bonuses paid despite missed STI gateway.
  • Finance-function instability: two CFO departures between Sep 2024 and Oct 2025; corrected 4E in Aug 2026.
  • Cash conversion: FY25 OCF −A$13.4m; FY26 FCF −A$4.1m after capex.
  • Geographic concentration: 94% of FY26 revenue from Australia.

Opportunities

  • Asia roll-up: organic Asia growth 13.2% plus annualisation of Haju (A$28.8m full-year revenue impact) and Somnotec.
  • ADF contract: five-year Defence supply contract from Q4 FY26 (≈A$40m p.a. per one aggregator).
  • Brisbane DC: fully operational June 2026, removing outside-storage costs flagged in FY26.
  • Offshoring: shifting ANZ administration to Asian shared services (FY27 plan).
  • New verticals: dental (AHP, Presidental), aesthetics ANZ, robotics, animal health, NZ wholesale launch.
  • Infinity recovery upside: A$9–13m range modelled vs A$9.3m booked, plus unvalued personal guarantees from Infinity's directors.
  • Capital return: buyback at a ~0.75x price-to-book could be accretive if funded from free cash flow.

Threats

  • Customer credit: Infinity loss of A$38.0m (gross ECL) demonstrates exposure; other pharmacy-group failures possible.
  • Price competition: Ramsay lost after a materially lower competitor bid (Jan 2026).
  • OEM disintermediation: orthopaedics and vision suppliers switching to direct models (FY26 release).
  • Cost inflation: fuel and freight costs (also cited by EBOS, which cut guidance in April 2026).
  • FX: A$19.4m FX translation loss in OCI (FY26); FX movement cost Med Tech A$2.4m of margin.
  • Refinancing: DFF and ABF mature June 2028; DFF carries a A$125m minimum drawdown and current classification.
  • Earn-out cash calls: A$56.0m of vendor conditional payables (A$22.3m current).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 Apr 2025Walstab transitions to NED (A$220k termination payment)Board reconfiguration; reduces independence count
May 2025Dental BU launched at Australian Dental CongressNew growth vertical
Jun 2025Owens & Minor contract logistics go-liveDrives +25% FY25 and +47% 1H26 logistics growth
Jun 2025New A$325m DFF and A$75m ABF (maturity Jun 2028)Refinancing completed
25 Jun 2025Riley named CEO effective 1 Jul 2025Leadership succession
2 Jul 2025AHP Dental acquiredDental scale-up
27 Aug 2025FY25 results: revenue A$3.61bn (+8.3% pro-forma), underlying EBITDA A$95.2m, underlying NPAT A$31.2mRevenue and EPS missed consensus (Simply Wall St: revenue −3.9%, EPS −31% vs estimates)
Aug–Sep 2025Infinity group repays >A$10m of A$57.1m debt in three monthsTemporary relief
30 Sep 2025FY25 AR: EY qualified opinion re Infinity receivable; A$125m debt reclassified current; four APAC targets in due diligenceGovernance/credit red flag
15 Oct 2025CFO Marcus Crowe resigns with immediate effectSecond CFO departure in ~13 months
28 Oct 2025Somnotec agreement signedAsia expansion
Nov 2025AGM: Chair cites Infinity non-payment and deliberate high stock levels for elevated year-end debtLeverage concerns
30 Nov 2025Haju Medical agreement signedLargest FY26 deal
15 Dec 2025Somnotec completesAsia revenue boost
17 Dec 2025Wesfarmers Health/API appoints receivers to 54 Infinity Priceline stores; administrators (KPMG/Teneo) appointed; PGC says it was not notified; shares fall ~13.5%Crystallises A$46.9m exposure
Jan 2026Further administrator appointments to Infinity entitiesCredit loss widens
16 Jan 2026Ramsay pharmacy wholesale exit announced (from 1 Feb 2026)~A$230m revenue loss; earnings-neutral claim
30 Jan 2026Fisher Biotec acquiredClinical Manufacturing
6 Feb 2026Pacific Medical Group acquiredHK logistics and agencies
25 Feb 20261H26: revenue A$1.9bn (+2.9%), underlying EBITDA A$49m (+3.1%), statutory loss A$21.3m after 100% Infinity provision; net debt A$287.5m (2.81x pro-forma); FY26 guidance reaffirmed; ADF contractStatutory loss; leverage peak
25 Feb 2026Riley appointed MD (1 Mar 2026); Collins becomes Executive DirectorSuccession completed
31 Mar 2026Transpacific Medical acquiredAsia/ANZ bolt-on
1 Apr 2026Haju Medical and Presidental/Rockpac completedAesthetics and dental
22 Apr 2026 (sector)Peer EBOS cuts EBITDA guidance for fuel/energy costsSector-wide fuel headwind also cited by PGC
3 Jun 2026An institutional holder ceases to be substantialRegister churn
Jun 2026Brisbane DC fully operationalRemoves outside-storage cost drag
29–30 Jun 2026Egglestone buys 200k shares at A$0.135; Walstab restructures 6m sharesModest insider buying
3 Jul 20265,996,911 shares issued to Riley (valued ~A$0.93m)Incentive vesting/issue
7 Aug 2026Infinity administrators issue updated estimated outcome analysis: A$9–13m recovery range for PGCBasis for A$9.3m recovery estimate
26 Aug 2026FY26 results: revenue A$3.68bn, underlying EBITDA A$97.2m, statutory NPAT −A$16.0m; no dividend; no FY27 guidance; buyback flaggedResults at low end of guidance
26 Aug 2026Corrected Appendix 4E released (typographical date errors)Minor disclosure-quality issue
28 Aug 2026AGM-related notice and director-interest notice—
29 Sep 2026FY26 Annual Report lodged–
Sep–Dec 2026 (expected)Infinity store sale completions modelledDetermines final recovery

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Region: Total rose from AUD 3,613.9 Mn in FY2025 to AUD 3,680.5 Mn in FY2026.
Paragon Care Limited — Revenue by Region
Series (AUD Mn)FY2025FY2026
Total3,613.93,680.5
Australia3,452.63,460.8
New Zealand6059.6
Asia101.3160.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Paragon Care Limited, FY26 Appendix 4E and Preliminary Final Report (26 Aug 2026) and corrected version (bulletin.webull.com)
  2. Paragon Care Limited, FY26 Full Year Financial Results release (26 Aug 2026) (bulletin.webull.com)
  3. Paragon Care Limited, 1H26 Results Release and Investor Presentation (25 Feb 2026) (paragoncare.com.au)
  4. Paragon Care Limited, Half Year Report FY26 (25 Feb 2026) — bulletin.webull.com
  5. Paragon Care Limited, FY25 Annual Report (30 Sep 2025) — - FY25 Annual Report.pdf (paragoncare.com.au)
  6. Paragon Care Limited, FY25 Results Release (27 Aug 2025) (announcements.asx.com.au)
  7. Paragon Care Limited, HY25 Results and Investor Presentation (27 Feb 2025) — ASX / paragoncare.com.au
  8. ASX announcements: CEO appointment (25 Jun 2025); CFO resignation (15 Oct 2025); Ramsay contract (16 Jan 2026); MD appointment (25 Feb 2026); CH2 merger (1 and 5 Mar 2024); Meditron and Western Biomedical (Oct 2015); Quantum merger (Nov 2021, Feb 2022)
  9. FY25 investor briefing transcript (27 Aug 2025) — paragoncare.com.au
  10. Baker McKenzie (Jun 2024); Herbert Smith Freehills and Lawyers Weekly (Mar 2022); SmallCaps (Mar 2024)
  11. Business News Australia; Australian Journal of Pharmacy; Finance News Network (Dec 2025 – Feb 2026, Infinity coverage)
  12. InvestSMART, Motley Fool Australia, Market Index, Simply Wall St, Fintel, stockanalysis.com, Quartr, Alphaspread (price, ownership and aggregator data — secondary)
  13. EBOS Group FY26 results (19 Aug 2026); Sigma Healthcare FY26 results (27 Aug 2026) — peer benchmarking

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.